DOI:
10.1055/s-00050348
Indian Journal of Medical and Paediatric Oncology
LinksClose Window
References
Mateos M-V, Cavo M, Blade J. et al.
Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): a randomised, open-label, phase 3 trial.
Lancet 2020;
395 (10218): 132-141
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.